0 11 SRC-related src-related JJ 12 27 proto-oncogenes proto-oncogene NNS 28 31 and and CC 32 45 transcription transcription NN 46 53 factors factor NNS 54 56 in in IN 57 64 primary primary JJ 65 70 human human JJ 71 72 T t NN 73 78 cells cell NNS 78 79 : : : 80 90 modulation modulation NN 91 93 by by IN 94 105 cyclosporin cyclosporin NN 106 107 A A NNP 108 111 and and CC 112 117 FK506 FK506 NNP 117 118 . . . 120 130 Activation Activation NNP 131 133 of of IN 134 135 T t NN 136 147 lymphocytes lymphocyte NNS 148 155 induces induce VBZ 156 169 transcription transcription NN 170 172 of of IN 173 178 genes gene NNS 179 187 encoding encode VBG 188 191 for for IN 192 203 lymphokines lymphokine NNS 203 204 . . . 205 218 Interleukin-2 interleukin-2 NN 219 220 ( ( ( 220 224 IL-2 il-2 NN 224 225 ) ) ) 226 230 gene gene NN 231 241 expression expression NN 242 244 is be VBZ 245 255 controlled control VBN 256 273 transcriptionally transcriptionally RB 274 276 by by IN 277 280 the the DT 281 292 cooperative cooperative JJ 293 301 activity activity NN 302 304 of of IN 305 313 specific specific JJ 314 330 trans-activating trans-activating JJ 331 338 factors factor NNS 339 343 that that WDT 344 348 bind bind VBP 349 351 to to TO 352 355 the the DT 356 360 IL-2 il-2 NN 361 369 enhancer enhancer NN 369 370 . . . 371 382 Cyclosporin Cyclosporin NNP 383 384 A A NNP 385 386 ( ( ( 386 389 CsA CsA NNP 389 390 ) ) ) 391 394 and and CC 395 400 FK506 FK506 NNP 401 408 inhibit inhibit VBP 409 412 the the DT 413 423 production production NN 424 426 of of IN 427 431 IL-2 il-2 NN 432 434 in in IN 435 436 T t NN 437 448 lymphocytes lymphocyte NNS 449 451 at at IN 452 455 the the DT 456 461 level level NN 462 464 of of IN 465 469 gene gene NN 470 483 transcription transcription NN 483 484 . . . 485 486 A a DT 487 493 member member NN 494 496 of of IN 497 500 the the DT 501 504 src src NN 505 509 gene gene NN 510 516 family family NN 516 517 , , , 518 521 the the DT 522 541 lymphocyte-specific lymphocyte-specific JJ 542 549 protein protein NN 550 558 tyrosine tyrosine NN 559 565 kinase kinase NNP 565 566 , , , 567 573 p56lck p56lck NN 573 574 , , , 575 578 has have VBZ 579 583 been be VBN 584 594 implicated implicate VBN 595 597 in in IN 598 602 IL-2 il-2 NN 603 613 production production NN 613 614 . . . 615 618 CsA CsA NNP 619 622 was be VBD 623 628 found find VBN 629 632 not not RB 633 635 to to TO 636 643 inhibit inhibit VB 644 647 lck lck NN 648 652 gene gene NN 653 663 expression expression NN 663 664 , , , 665 668 nor nor CC 669 672 the the DT 673 681 activity activity NN 682 684 of of IN 685 688 the the DT 689 692 lck lck NN 693 697 gene gene NN 698 705 product product NN 705 706 . . . 707 714 However however RB 714 715 , , , 716 719 CsA CsA NNP 720 723 and and CC 724 729 FK506 FK506 NNP 730 737 inhibit inhibit VBP 738 741 the the DT 742 752 appearance appearance NN 753 755 of of IN 756 759 DNA DNA NNP 760 767 binding binding NN 768 776 activity activity NN 777 779 of of IN 780 787 factors factor NNS 788 792 that that WDT 793 797 bind bind VBP 798 800 to to TO 801 804 the the DT 805 810 NF-AT nf-at NN 811 814 and and CC 815 819 AP-1 ap-1 NN 820 825 sites site NNS 826 828 in in IN 829 832 the the DT 833 837 IL-2 il-2 NN 838 846 enhancer enhancer NN 846 847 . . . 848 853 Since since IN 854 857 the the DT 858 867 induction induction NN 868 870 of of IN 871 876 NF-AT NF-AT NNP 877 880 and and CC 881 885 AP-1 AP-1 NNP 886 888 is be VBZ 889 896 induced induce VBN 897 899 by by IN 900 903 the the DT 904 908 same same JJ 909 916 stimuli stimulus NNS 917 921 that that WDT 922 931 stimulate stimulate VBP 932 936 IL-2 il-2 NN 937 947 production production NN 947 948 , , , 949 954 these these DT 955 962 results result NNS 963 971 indicate indicate VBP 972 976 that that IN 977 980 the the DT 981 998 immunosuppressant immunosuppressant JJ 999 1005 action action NN 1006 1008 of of IN 1009 1012 CsA CsA NNP 1013 1016 and and CC 1017 1022 FK506 FK506 NNP 1023 1025 is be VBZ 1026 1033 exerted exert VBN 1034 1036 at at IN 1037 1040 the the DT 1041 1046 level level NN 1047 1049 of of IN 1050 1055 these these DT 1056 1072 trans-activating trans-activating JJ 1073 1080 factors factor NNS 1080 1081 . . .